Richard Morgan, MD
For patients with acute myeloid leukemia (AML), HXR9 is designed to prevent the shutdown of various genes involved in apoptosis—the natural process that causes unhealthy and damaged cells to die, according to Richard Morgan, MD.
, Morgan, professor, director of the Institute for Cancer Therapeutics, University of Bradford, discussed this recent research involving therapy with HXR9 for patients with AML.
OncLive: Can you please provide an overview of the research?
We’re interested in what’s called HOX
genes. These have been looked at for a while but were originally investigated in the context of the early development of the embryo. For example, they specify the identities of certain cells and tissues. Generally, it’s silenced in most adult cells but it became apparent over the last few decades that cancer cells, particularly AML, switch HOX
genes back on as part of the oncogenic process.
... to read the full story